Eptifibatide Acetate Powder 98% Cas No.148031-34-9
Product source: Artificially synthesized cyclic heptapeptide
Content specification: ≥ 98%
CAS number: 148031-34-9
Detection method: HPLC
Active ingredient: cyclic heptapeptide
Product mesh: 80-120 mesh
Product Description: White to off white powder
Product Usage: Medical Applications
Product storage: -20 ° C vacuum freeze-drying storage
Shelf life: 24-36 months
Products Description
Xi'an Tihealth Biotechnology
High purity Eptifibatide Acetate Powder
Xi'an Tihealth specializes in producing high-purity acetic acid eptifibatide that meets pharmaceutical standards. This product is synthesized using advanced technology, with a stable main component content of ≥ 98.0% (HPLC). It strictly follows GMP standards to implement full process quality control, ensuring batch consistency and low impurity levels. As a highly selective antagonist of platelet GPIIb/IIIa receptors, it is a key component in the preparation of drugs for acute coronary syndrome and PCI adjuvant therapy. We are committed to providing reliable and stable supply of pharmaceutical grade raw materials for our partners.
Products Function
Rapid inhibition of platelet aggregation:
By reversibly blocking the binding of fibrinogen to the GPIIb/IIIa receptor on the platelet surface, it prevents thrombus formation and effectively reduces the risk of acute ischemic events.
Products Aplication
Cardiovascular disease treatment:
▶ Acute Coronary Syndrome (ACS):
◑ Unstable Angina Pectoris (UA)
◑ Non-ST-segment Elevation Myocardial Infarction (NSTEMI)
▶ Medications for adjunctive treatment of Percutaneous Coronary Intervention (PCI):
◑ Prevention of thromboembolic complications during and after the procedure
◑ Reduction of the recurrence rate of myocardial infarction
Advantages over similar drugs
● Clear structure: Synthetic heptapeptide (non-antibody type), with a small molecular weight (832 Da), no risk of immunogenicity.
● Quick onset: Peak effect achieved within 5 minutes after intravenous administration, suitable for acute intervention scenarios.
● Clinical validation: Reduced the risk of 48-hour myocardial infarction/death in ACS patients by 36% (ESPRIT trial).
Hot Tags: Eptifibatide Acetate Powder 98% Cas No.148031-34-9, China Eptifibatide Acetate Powder 98% Cas No.148031-34-9 manufacturers, suppliers, factory, Earthworm Protein Peptide, Glutathione Powder, Goji Berry Peptide, peptides, Soybean Peptide
You Might Also Like
Send Inquiry